3.
4.
5.
6.
Schiffer CA, Lee EJ, Ness PM, Reilly J. Clinical evaluation of platelet concentrates stored for one to five days. Blood. 1986;67:1591–4.PubMed
7.
Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood. 1981;57:395–8.PubMed
8.
9.
Duquesnoy RJ, Testin J, Aster RH. Variable expression of w4 and w6 on platelets: possible relevance to platelet transfusion therapy of alloimmunized thrombocytopenic patients. Transplant Proc. 1977;9:1829–31.PubMed
10.
Schiffer CA, O’Connell B, Lee EJ. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets. Blood. 1989;74:1172–6.PubMed
11.
Freireich EJ, Judson G, Levin RH. Separation and collection of leukocytes. Cancer Res. 1965;25:1516–20.PubMed
12.
13.
Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997;337:1861–9.
14.
15.
O’Connell BA, Lee EJ, Rothko K, Hussein MA, Schiffer CA. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates. Blood. 1992;79:527–31.PubMed
16.
17.
18.
19.
20.
Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med. 1997;337:1870–5.PubMedCrossRef